Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for treatment of multiple solid tumor indications. Co.'s main therapeutic candidate is gedatolisib, a pan-PI3K/mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other approved and investigational therapies that target PI3K or mTOR alone or together. Co.'s therapeutic candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin. The CELC average annual return since 2017 is shown above.
The Average Annual Return on the CELC average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CELC average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CELC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CELC Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
